EXACT THERAP. AS NK 0004
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more
EXACT THERAP. AS NK 0004 (56F) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EXACT THERAP. AS NK 0004 (56F) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EXACT THERAP. AS NK 0004 - Net Assets Trend (None–None)
This chart illustrates how EXACT THERAP. AS NK 0004's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EXACT THERAP. AS NK 0004 (None–None)
The table below shows the annual net assets of EXACT THERAP. AS NK 0004 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EXACT THERAP. AS NK 0004's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EXACT THERAP. AS NK 0004 Competitors by Market Cap
The table below lists competitors of EXACT THERAP. AS NK 0004 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WANdisco plc
PINK:WANSF
|
$2.50 Million |
|
IDeA Indonesia Akademi Tbk PT
JK:IDEA
|
$2.50 Million |
|
Transition Metals Corp
PINK:TNTMF
|
$2.50 Million |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
$2.50 Million |
|
Kumpulan Jetson Bhd
KLSE:9083
|
$2.50 Million |
|
NORFOLK SOUTHERN - Dusseldorf Stock Exchang
DU:NFS
|
$2.50 Million |
|
Mec Resources Ltd
AU:MMR
|
$2.50 Million |
|
Chaoprayamahanakorn Public Company Limited
BK:CMC
|
$2.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EXACT THERAP. AS NK 0004's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EXACT THERAP. AS NK 0004's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EXACT THERAP. AS NK 0004 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EXACT THERAP. AS NK 0004's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EXACT THERAP. AS NK 0004 (56F) | €- | N/A | N/A | $2.50 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |